SK Bioscience, full-fledged subscription… Does the bio-farm craze reappear?

Input 2021.03.01 16:08

In the first half of this year, SK Bioscience, a vaccine specialty company that is regarded as an IPO, has signed up for public offerings in earnest this month.

According to the financial investment industry on the 1st, SK Bioscience will begin the process of applying for public offering stocks starting from the forecast of demand for institutional investors to determine the public offering price on the 3rd to 4th. At this time, based on the public offering price, the company will receive an offer for general public offering shares on the 9th to 10th and will be listed on the stock market on the 18th.

SK Bioscience is a vaccine company that was spun off by SK Chemicals in July 2018. For this reason, it is compared with the IPO Daere SK Biopharm, which was listed last year. At the time, it was noted that SK Biopharm, a new drug developer, was the first domestic pharmaceutical company to obtain approval for direct marketing of a new drug developed by the US Food and Drug Administration (FDA). In the phase of the novel coronavirus (Corona 19), SK Bioscience is drawing attention from investors as it is a vaccine development and consignment producer.

Accordingly, SK Bioscience is expected to bring about a fever for public offerings as well as SK Biopharm. SK Biopharm, which opened its IPO craze last year, recorded a competition rate of 835.66:1 with 1076 domestic and foreign organizations participating in the demand forecast last year. Following this, the public offering offered 391,5662 shares for 48,000 won in general, breaking the record for the record with a margin of 30,989.9 billion won. However, this record was broken by the Kakao Games (58,554.3 billion won) IPO.

On the day of listing, SK Biopharm recorded a so-called’tasang’, which increased to the price limit after forming an initial price at twice the public offering price. After that, it closed at the upper limit for two more days.

SK Bioscience’s total number of public offerings is 22.95 million shares, the desired public offering price is 49,000-65,000 won, and the public offering amount is at least 1.124.5 billion won. Sales and net income in 2019 were KRW 183.9 billion and KRW 14.6 billion, respectively, significantly exceeding SK Biopharm, which recorded KRW 123.8 billion in sales and 9 billion KRW in net loss in the same year.

However, there are also observations that the craze for SK Bioscience will not be as strong as SK Biopharm. Not only is the stock bull market and liquidity stagnating, but the wind over vaccine-related stocks has blown away.